Catheter Precision, Inc. 10-K — AI Bull & Bear Analysis

The 10-K paints a picture of a company at a critical inflection point, where high-margin product potential is warring with a dire balance sheet. The successful scaling of LockeT and the strategic pivot toward a holding company structure with FLYTE suggest a management team capable of creative capital engineering. However, the immediate risk is not clinical, but financial; the company is essentially racing against its own cash burn to reach the next regulatory catalyst. Investors are left weighing the potential of a $14.5 billion electrophysiology market against the very real possibility of further massive dilution or a liquidity event. The upcoming Q2 2025 FDA submission for VIVO serves as the primary binary event that will determine if the company can transition from a survival-mode entity to a growth-stage medical technology leader.